Technical Analysis for CRGX - CARGO Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | -5.41% | |
| Inside Day | Range Contraction | -5.41% | |
| Gapped Up | Strength | -5.41% | |
| New 52 Week High | Strength | -4.99% | |
| Gapped Up | Strength | -4.99% | |
| New 52 Week Closing High | Bullish | -8.78% | |
| Pocket Pivot | Bullish Swing Setup | -8.78% | |
| Wide Range Bar | Range Expansion | -8.78% | |
| New 52 Week High | Strength | -8.78% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Support | about 16 hours ago |
| Down 5% | about 17 hours ago |
| Down 1 ATR | about 17 hours ago |
| Down 3% | about 18 hours ago |
| Fell Below 10 DMA | about 18 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Immune System Tumor Cancer Immunotherapy Gene Therapy Therapies For Cancer Antigen T Cells Cd22 Siglec
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Immune System Tumor Cancer Immunotherapy Gene Therapy Therapies For Cancer Antigen T Cells Cd22 Siglec
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.29 |
| 52 Week Low | 13.14 |
| Average Volume | 167,866 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 15.24 |
| Average True Range | 0.99 |
| RSI (14) | 50.25 |
| ADX | 0.0 |
| +DI | 16.15 |
| -DI | 22.24 |
| Chandelier Exit (Long, 3 ATRs) | 14.31 |
| Chandelier Exit (Short, 3 ATRs) | 16.12 |
| Upper Bollinger Bands | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.21 |
| MACD Signal Line | 0.15 |
| MACD Histogram | 0.0583 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.78 | ||||
| Resistance 3 (R3) | 17.91 | 17.06 | 17.29 | ||
| Resistance 2 (R2) | 17.06 | 16.32 | 17.00 | 17.13 | |
| Resistance 1 (R1) | 15.96 | 15.86 | 15.54 | 15.83 | 16.97 |
| Pivot Point | 15.11 | 15.11 | 14.90 | 15.05 | 15.11 |
| Support 1 (S1) | 14.01 | 14.37 | 13.59 | 13.89 | 12.75 |
| Support 2 (S2) | 13.17 | 13.91 | 13.10 | 12.59 | |
| Support 3 (S3) | 12.07 | 13.17 | 12.43 | ||
| Support 4 (S4) | 11.94 |
